An engineered cell comprising an Anti-CD19 and Anti-CD20 chimeric antigen receptor, a nucleic acid or vector, a kit and their use
The engineered cell with a humanized CD19/CD20 bispecific CAR addresses the limitations of single-antigen targeting by enhancing immune response and reducing relapse risk, providing improved therapeutic efficacy for cancer and autoimmune diseases.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- AVENCELL THERAPEUTICS INC
- Filing Date
- 2025-12-19
- Publication Date
- 2026-07-02
AI Technical Summary
Conventional CAR technology is limited by the restriction of engineered T cell retargeting to a single antigen, leading to the risk of tumor escape variants during treatment, and there is a need for improved immune response and reduced risk of relapse in cancer, infectious, or autoimmune disease treatments.
An engineered cell comprising a chimeric antigen receptor (CAR) with humanized CD19 and CD20 binding domains, specifically designed with optimized CDR sequences and a flexible linker, allowing simultaneous targeting of both antigens, enhancing immune response and reducing relapse risk.
The engineered CAR provides enhanced potency and specificity for CD19 and CD20 antigens, improving treatment efficacy and reducing the likelihood of tumor escape variants, thereby offering a more effective therapeutic option for cancer and autoimmune diseases.
Smart Images
Figure IB2025063221_02072026_PF_FP_ABST